KEY RESULTS OF THE ROUND TABLE

SARTURIUS

'THE RISE OF AUTONOMOUS LABS IN LIFE SCIENCES"

— A new acceleration in drug discovery is emerging from autonomous labs

Drug discovery still loses time, money and talent to slow laboratory workflows, fragmented datasets and late-stage clinical failures. At the same time, biology is becoming more complex and international competition is tightening. Europe needs interoperable autonomous labs, stronger data infrastructure and genuinely cross-disciplinary scientific talent to keep pace.

Autonomous labs bring together robotics, artificial intelligence (AI), high-quality omics datasets and automated experiment cycles to industrialise scientific discovery. They reduce human error, accelerate design-make-test loops and link molecular insights more directly to patient data. But their impact depends on shared platforms, rigorous data governance and researchers who understand how to integrate automation into real scientific decision-making.

THE PANEL CALL TO ACTION:

1 — Build shared platforms for autonomous labs.

Develop common operating systems, data standards and instrument interfaces so discovery workflows can run reproducibly across sites rather than in isolated automation islands.

2 — Make high-quality, Findable, Accessible, Interoperable and Reusable (FAIR) data a strategic asset.

Link electronic health records (EHRs) with omics datasets through publicprivate partnerships and generate synthetic data where needed, ensuring Al models can train on reliable, well-curated information.

3 — Redesign drug discovery around AI, automation and cross-disciplinary skills.

Shift academic and industrial training towards platform thinking, data analysis and systems integration, preparing scientists to collaborate across biology, Al and robotics.

4 — Establish robust governance for data and Al.

Set clear quality metrics, validation protocols and quardrails so automated workflows remain reproducible, bias-aware and compatible with good practice (GxP)-style regulation.

5 — Use automation to amplify human judgement, not replace it.

Design autonomous labs so Al proposes experiments, detects anomalies and simplifies complex reasoning, while humans set goals, interpret unexpected findings and decide when to override or reframe what the system is doing, preserving room for serendipity and truly novel discoveries.

This event is supported by Sartorius and assembled in the framework of the Falling Walls Science Summit 2025 in Berlin. The Falling Walls Science Summit is a leading international, interdisciplinary, and intersectoral forum for scientific breakthroughs. It commemorates the fall of the Berlin Wall and aims to promote dialogue between science and society.

PANELLISTS

Cord Dohrmann

Chief Scientific Officer, Evotec

Ola Engkvist

Executive Director, AstraZeneca, Chalmers University of Technology

Rob Harkness

CTO. Biosero

Mark Owen

Senior Scientist, Corporate Research, Sartorius

Krysia Sommers

Head of Strategic PR, Bayer, Moderator

CONTACT

Falling Walls Foundation gGmbH

Kochstraße 6-7 10969 Berlin

Web: www.falling-walls.com

PARTNER REQUEST

Dr. Andreas Kosmider Managing Director andreas.kosmider@falling-walls.com

Phone: +49 30 609 883 97 28 Mobile: +49 172 273 75 77

PRESS REQUEST

Felix Mihalek PR Manager

phone: +49 30 60 988 39 780

mail: felix.mihalek@falling-walls.com



fallingwalls



FallingWallsFoundation



falling-walls-foundation